Denali Therapeutics (DNLI) Equity Ratio (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Equity Ratio data on file, last reported at 0.73 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.73, down 17.16% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.73 (down 17.16% YoY), and the FY2025 annual result was 0.89, down 1.05% from the prior year.
• Equity Ratio retreated to 0.73 in Q1 2026 per DNLI's latest filing, from 0.89 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q2 2024 and troughed at 0.66 in Q3 2022.
• A 5-year average of 0.83 and a median of 0.88 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2026: Equity Ratio surged 36.82% in 2023, then declined 17.16% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.71 in 2022, then gained by 25.15% to 0.89 in 2023, then gained by 0.16% to 0.89 in 2024, then declined by 1.05% to 0.89 in 2025, then declined by 17.39% to 0.73 in 2026.
• Business Quant data shows DNLI's Equity Ratio at 0.73 in Q1 2026, 0.89 in Q4 2025, and 0.88 in Q3 2025.